George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 345.00
Bid: 340.00
Ask: 350.00
Change: 0.00 (0.00%)
Spread: 10.00 (2.941%)
Open: 345.00
High: 345.00
Low: 345.00
Prev. Close: 345.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

23 Jan 2018 13:32

RNS Number : 6888C
MaxCyte, Inc.
23 January 2018
 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Total Voting Rights

 

Maryland, USA - 23 January 2018: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 18,293 new shares of common stock of $0.01 each in the Company (the "Common Stock") were issued from the blocklisting facility granted 5 May 2017.

The total issued stock capital of the Company has consequently increased to 50,914,669, Common Stock. There is no Common Stock held in treasury. Therefore, the total number of voting rights in the Company is 50,914,669. Stockholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 35,401,561 and the number of restricted shares of Common Stock trading under the symbol 'MXCR' is 15,513,108. The number of Common Stock capable of being issued under the blocklisting facility is 899,858 Common Stock.

 

For further information please contact:

 

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

Panmure Gordon

Freddy Crossley (Corporate Finance)

Fabien Holler

Tom Salvesen (Corporate Broking)

 

+44 (0) 20 7886 2500

 

Financial PR Adviser

Consilium Strategic Communications

+44 (0)203 709 5700

maxcyte@consilium-comms.com

Mary-Jane Elliott

Chris Welsh

Lindsey Neville

 

 

 

About MaxCyte

 

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

 

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

 

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

 

For more information visit http://www.maxcyte.com/

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRFKNDNNBKDDDB
Date   Source Headline
20th Mar 202410:16 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
20th Mar 202410:05 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
13th Mar 20247:05 amRNSFiling of form 10-K for FY ended December 31, 2023
13th Mar 20247:00 amRNSReports Q4 & FY 2023 Financial Results
6th Mar 20248:58 amRNSTR-1: Notification of major holdings
5th Mar 20247:00 amRNSPreliminary FY Results & 2024 Guidance
1st Mar 20245:57 pmRNSTotal Voting Rights
29th Feb 20249:21 amRNSExercise of options and PDMR dealing
26th Feb 20247:00 amRNSTR-1: Notification of major holdings
9th Feb 20241:05 pmRNSNotice of Results
1st Feb 20249:24 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSDirector/PDMR Shareholding
30th Jan 20242:29 pmRNSHolding(s) in Company
30th Jan 20241:05 pmRNSSigning of Strategic Platform License
29th Jan 20244:52 pmRNSTR-1: Notification of major holdings
29th Jan 20247:00 amRNSFiling of Form 8-K
23rd Jan 20241:05 pmRNSSigning of Strategic Platform License
9th Jan 20247:00 amRNSPreliminary Unaudited Q4 and FY 2023 Results
5th Jan 20247:00 amRNSGrant of Options and PDMR Dealing
3rd Jan 20241:05 pmRNSSigning of Strategic Platform License
2nd Jan 20249:23 amRNSTotal Voting Rights
2nd Jan 20247:00 amRNSConfirmation of Board change
29th Dec 20237:00 amRNSExercise of options and PDMR dealing
12th Dec 20237:00 amRNSCEO Transition and Revenue Guidance Update
7th Dec 20239:50 amRNSExercise of options and PDMR dealing
4th Dec 20237:00 amRNSExercise of options and PDMR dealing
1st Dec 20235:43 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of options and PDMR dealing
17th Nov 20237:00 amRNSExercise of options and PDMR dealing
16th Nov 20231:05 pmRNSMaxCyte Joins the Alliance for mRNA Medicines
9th Nov 20237:01 amRNSFiling of Form 10-Q
9th Nov 20237:00 amRNSThird Quarter Results
7th Nov 20237:00 amRNSParticipation in Upcoming Investor Conferences
1st Nov 20231:12 pmRNSTotal Voting Rights
5th Oct 20237:00 amRNSPreliminary Q3 Revenue & FY Revenue Guidance
2nd Oct 20234:03 pmRNSTotal Voting Rights
13th Sep 20232:28 pmRNSTR-1: Notification of major holdings
12th Sep 20231:21 pmRNSTR-1: Notification of major holdings
5th Sep 20234:17 pmRNSTR-1: Notification of major holdings
5th Sep 20231:05 pmRNSBaird Global Healthcare Conference Participation
4th Sep 20231:32 pmRNSTR-1: Notification of major holdings
4th Sep 20237:00 amRNSTotal Voting Rights
1st Sep 20239:01 amRNSExercise of options and PDMR dealing
18th Aug 20235:25 pmRNSTR-1
17th Aug 20234:27 pmRNSTR-1: Notification of major holdings
17th Aug 20237:00 amRNSTR-1: Notification of Major Holdings
10th Aug 20237:25 amRNSFiling of Form 10-Q
10th Aug 20237:00 amRNSSecond Quarter and Half-Year Results
8th Aug 20233:15 pmRNSTR-1: Notification of major holdings
7th Aug 20235:01 pmRNSTotal Voting Rights and Block Listing Return

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.